Recurrent Adult Immunoblastic Large Cell Lymphoma Completed Phase 2 Trials for Cyclophosphamide (DB00531)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01427881Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesTreatment
NCT00049504Fludarabine Phosphate, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Total-Body Irradiation, and Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerTreatment
NCT00073918Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTreatment
NCT01093586Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTreatment
NCT01177371High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaTreatment